BSE Live
Dec 10, 12:39Prev. Close
190.10
Open Price
189.95
Bid Price (Qty.)
189.45 (141)
Offer Price (Qty.)
189.75 (136)
NSE Live
Dec 10, 12:38Prev. Close
190.11
Open Price
189.61
Bid Price (Qty.)
189.53 (2)
Offer Price (Qty.)
189.69 (3)
| Profit & Loss account of Marksans Pharma (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 1,165.97 | 850.06 | 652.68 | 647.57 | 591.74 | |
| Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue From Operations [Net] | 1,165.97 | 850.06 | 652.68 | 647.57 | 591.74 | |
| Total Operating Revenues | 1,174.37 | 853.27 | 655.20 | 658.29 | 599.55 | |
| Other Income | 69.83 | 62.07 | 60.48 | 42.25 | 31.16 | |
| Total Revenue | 1,244.21 | 915.35 | 715.69 | 700.54 | 630.70 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 537.18 | 407.15 | 338.49 | 327.99 | 291.29 | |
| Purchase Of Stock-In Trade | 102.06 | 79.03 | 66.15 | 45.71 | 46.07 | |
| Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | 0.70 | -7.25 | -10.19 | 3.89 | 0.55 | |
| Employee Benefit Expenses | 101.68 | 77.19 | 56.09 | 60.46 | 54.64 | |
| Finance Costs | 1.17 | 0.99 | 3.61 | 3.80 | 5.34 | |
| Depreciation And Amortisation Expenses | 29.45 | 29.13 | 16.74 | 17.66 | 15.19 | |
| Other Expenses | 228.71 | 157.21 | 112.76 | 106.52 | 93.28 | |
| Total Expenses | 1,000.95 | 743.45 | 583.65 | 566.03 | 506.37 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 243.26 | 171.89 | 132.04 | 134.51 | 124.33 | |
| Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | 243.26 | 171.89 | 132.04 | 134.51 | 124.33 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 51.38 | 37.01 | 30.35 | 30.01 | 28.19 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | 2.84 | 0.68 | -0.17 | 0.50 | -2.24 | |
| Tax For Earlier Years | 0.76 | 0.45 | -1.01 | 0.01 | 0.00 | |
| Total Tax Expenses | 54.99 | 38.13 | 29.17 | 30.52 | 25.95 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 188.27 | 133.76 | 102.87 | 103.99 | 98.38 | |
| Profit/Loss From Continuing Operations | 188.27 | 133.76 | 102.87 | 103.99 | 98.38 | |
| Profit/Loss For The Period | 188.27 | 133.76 | 102.87 | 103.99 | 98.38 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | 4.15 | 2.95 | 2.48 | 2.54 | 2.40 | |
| Diluted EPS (Rs.) | 4.15 | 2.95 | 2.48 | 2.54 | 2.40 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 27.19 | 22.66 | 10.17 | 10.23 | 4.09 | |
| Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Equity Dividend Rate (%) | 80.00 | 60.00 | 50.00 | 25.00 | 25.00 |
26.11.2025
Marksans Pharma Consolidated September 2025 Net Sales at Rs 720.41 crore, up 12.23% Y-o-Y
24.11.2025
Marksans Pharma Standalone September 2025 Net Sales at Rs 320.44 crore, up 3.83% Y-o-Y
09.09.2025
Marksans Pharma Standalone June 2025 Net Sales at Rs 319.73 crore, up 25.62% Y-o-Y
20.05.2025
Marksans Pharma Consolidated March 2025 Net Sales at Rs 708.46 crore, up 26.51% Y-o-Y